mRNA vaccine platform demonstrates 87% efficacy against H5N1 avian influenza in phase II trial

Feldman RA, Fuhr R, Smolenov I, et al. • The Lancet • PMID SEED005

Rate this summary
★ ★ ★ ★ ★
✨ AI-Generated Summary

Using the same mRNA technology developed for COVID-19 vaccines, researchers achieved 87% protection against bird flu in a clinical trial, with results suggesting the platform could be rapidly adapted in the event of a pandemic.

⚠ AI summaries are generated automatically and may contain errors. Always refer to the original abstract and full article for clinical or research decisions.

Abstract

A randomized, double-blind, placebo-controlled phase II trial of an mRNA-based H5N1 influenza vaccine in 400 healthy adults demonstrated 87% vaccine efficacy against laboratory-confirmed H5N1 infection and a favorable safety profile over 12 months of follow-up.

← All Research
How would you rate this summary?
Your feedback helps us improve the quality of our AI summaries.
★ ★ ★ ★ ★
What did you like about this summary?
What did you not like about this summary?
Anything else you'd like to see covered?
Report an error
All reports are reviewed before any changes are made.
What type of error are you reporting?
Which part does this relate to?
Please describe the error
Be as specific as possible — include the correct information if you know it.
Highlight mode — select the text containing the error
Click and drag over the relevant text, then click Confirm.
✓
Thank you
Your response helps us improve the quality of our AI summaries.